A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

Blood

Volumn 99, Issue 8, 2002, Pages 2712-2719

  Carpenter, Paul A ^a,b   Appelbaum, Frederick R ^a,b   Corey, Lawrence ^a,b   Joachim Deeg, H ^b   Doney, Kris ^a,b   Gooley, Theodore ^a,b   Krueger, James ^a,b   Martin, Paul ^a,b   Pavlovic, Sandra ^a,b   Sanders, Jean ^a,b   Slattery, John ^a,b   Levitt, Daniel ^a,b   Storb, Rainer ^a,b   Woolfrey, Ann ^a,b   Anasetti, Claudio ^a,b  

^a USA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY CD3; STEROID; TACROLIMUS; VISILIZUMAB;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CELL SPECIFICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DNA DETERMINATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTOPENIA; MALE; PRIORITY JOURNAL; STEROID THERAPY; SURVIVAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

EID: 0037089222     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.8.2712     Document Type: Article

References (42)

1. Memotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
2. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors
3. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation
4. A retrospective analysis of therapy for acute graft-versushost disease: Secondary treatment
5. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome
6. Anti-thymocyte globulin (ATG) for steroid-resistant acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: A costly therapy with limited benefits
7. Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin
8. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance
9. 2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens
10. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro
11. Human IgG2 variants of chimeric anti-CD3 are non-mitogenic to T cells
12. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees
13. Anti-CD3 murine monoclonal isotype switch variants tested for toxicity and immunologic monitoring in four chimpanzees
14. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells
15. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors
16. Preclinical and phase I and II trials of rituximab
17. Treatment of acute graft-versus-host disease with a non-mitogenic anti-CD3 monoclonal antibody
18. Human herpesvirus 6 reactivation and encephalitis in allogeneic marrow transplant recipients
19. Sensitive method for detection of human herpesviruses 6 and 7 in saliva collected in field studies
20. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CLTA41g) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
21. Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen
22. Monoclonal antibodies identifying a novel T-cell antigen and la antigens of human lymphocytes
23. Overview of postransplant B-cell lymphoproliferative disorders
24. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin
25. Treatment of acute graft-versus-host disease with humanized anti-Tac: An antibody that binds to the interleukin-2 receptor
26. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute-graftversus-host disease
27. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody, ABXCBL
28. Anti-CD3 antibody HuM291 induces peripheral T cell apoptosis in patients with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation
29. Monoclonal antibody 1 F5 (anti-CD20) serotherapy of human B cell lymphomas
30. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: Distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation
31. Treatment of acute graft-versus-host disease with a non-mitogenic anti-CD3 monoclonal antibody
32. Treatment of acute-graft-versus-host-disease with monoclonal antibody OKT3: Clinical results and effect on circulating T lymphocytes
33. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study
34. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation
35. Risks of developing Epstein-Barr Virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants
36. Transplantation of megadoses of purified haploidentical stem cells
37. Anti-B cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
38. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hematopoietic stem-cell transplantation
39. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
40. Detection and quantification of virus DNA in plasma of patients with Epstein-Barr virus-associated diseases
41. Detection of cell-free Epstein-Barr virus DNA in serum during acute infectious mononucleosis
42. Osterhaus ADME. Development of a real-time quantitative assay for detection of Epstein-Barr virus